Lannett Company, Inc announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg and 8 mg, the generic equivalent of Purdue Pharmaceuticals’ (formerly Abbott’s) Dilaudid® Tablets 2 mg, 4 mg and 8 mg.

According to Wolters Kluwer, U.S. sales in 2008 of both generic and brand Hydromorphone Hydrochloride Tablets, 2 mg, 4 mg and 8 mg were $170 million at Average Wholesale Price. Lannett’s Cody Laboratories will manufacture the active pharmaceutical ingredient used in the company’s Hydromorphone products. Lannett expects to commence marketing within the next few weeks.

Last Trade: 6.35
Trade Time: 10:17AM ET
Change: Down 0.40 (5.93%)
Prev Close: 6.75
Open: 6.79
Day’s Range: 6.32 – 6.79
52wk Range: 1.60 – 9.74
Volume: 21,254
Avg Vol (3m): 38,320
Market Cap: 156.84M

About Lannett Co. Inc.

Lannett Company, Inc. develops, manufactures, markets, and distributes generic versions of pharmaceutical products in the United States. The company manufactures and/or sells various prescription products. Its product portfolio includes acetazolamide, baclofen, and bethanechol chloride tablets; amantadine gel capsules; butalbital, aspirin, and caffeine with codeine phosphate, danazol, and clindamycin HCl capsules; cocaine topical solution; and dicyclomine tablets and capsules. The company’s products also comprise digoxin, dipyridamole, doxycycline, doxycycline hyclate, esterified estrogen and methyltestoterone, hydrochlorothiazide, hydromorphone HCl, and levothyroxine sodium tablets; morphine sulfate oral solutions; and OB-natal one gel capsules.